EP2493926 - FUNCTION MODIFYING NAV 1.7 ANTIBODIES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 15.01.2021 Database last updated on 24.08.2024 | |
Former | The patent has been granted Status updated on 07.02.2020 | ||
Former | Grant of patent is intended Status updated on 23.10.2019 | ||
Former | Examination is in progress Status updated on 23.12.2016 | Most recent event Tooltip | 08.07.2022 | Lapse of the patent in a contracting state New state(s): MK | published on 10.08.2022 [2022/32] | Applicant(s) | For all designated states UCB Biopharma SRL Allée de la Recherche 60 1070 Brussels / BE | [2020/11] |
Former [2020/02] | For all designated states UCB Biopharma SRL Allé de la Recherche 60 1070 Brussels / BE | ||
Former [2015/30] | For all designated states UCB Biopharma SPRL Allée de la Recherche 60 1070 Brussels / BE | ||
Former [2012/36] | For all designated states UCB Pharma, S.A. 60, allée de la Recherche 1170 Brussels / BE | Inventor(s) | 01 /
MILLER, Karen Margrete UCB Pharma S.A. 60 Allée de la Recherche B-1070 Brussels / BE | 02 /
DE RYCK, Marc Roger UCB Pharma S.A. 60 Allée de la Recherche B-1070 Brussels / BE | 03 /
WOLFF, Christian Gilbert J. UCB Pharma S.A. 60 Allée de la Recherche B-1070 Brussels / BE | 04 /
LAWSON, Alastair David Griffiths UCB Celltech 208 Bath Road Slough Berkshire SL1 3WE / GB | 05 /
FINNEY, Helene Margaret UCB Celltech 208 Bath Road Slough Berkshire SL1 3WE / GB | 06 /
BAKER, Terence Seward UCB Celltech 208 Bath Road Slough Berkshire SL1 3WE / GB | [2012/36] | Representative(s) | UCB Intellectual Property c/o UCB Celltech IP Department 208 Bath Road Slough, Berkshire SL1 3WE / GB | [2020/11] |
Former [2012/36] | Blanchard, Amanda Jane UCB Celltech 208 Bath Road Slough, Berkshire SL1 3WE / GB | Application number, filing date | 10770839.8 | 27.10.2010 | [2020/11] | WO2010EP66276 | Priority number, date | US20090255202P | 27.10.2009 Original published format: US 255202 P | [2012/36] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2011051350 | Date: | 05.05.2011 | Language: | EN | [2011/18] | Type: | A1 Application with search report | No.: | EP2493926 | Date: | 05.09.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.05.2011 takes the place of the publication of the European patent application. | [2012/36] | Type: | B1 Patent specification | No.: | EP2493926 | Date: | 11.03.2020 | Language: | EN | [2020/11] | Search report(s) | International search report - published on: | EP | 05.05.2011 | Classification | IPC: | C07K16/28 | [2012/36] | CPC: |
C07K16/28 (EP,US);
A61K39/3955 (US);
A61P25/04 (EP);
A61P29/00 (EP);
A61P43/00 (EP);
A61K2039/505 (US);
C07K2317/21 (US);
C07K2317/24 (US);
C07K2317/31 (US);
C07K2317/34 (US);
C07K2317/54 (US);
C07K2317/55 (US);
C07K2317/56 (US);
C07K2317/565 (EP,US);
C07K2317/622 (US);
C07K2317/76 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2012/36] | Extension states | BA | 29.05.2012 | ME | 29.05.2012 | Title | German: | FUNKTIONELLE MODIFIZIERUNG VON NAV1.7-ANTIKÖRPERN | [2012/36] | English: | FUNCTION MODIFYING NAV 1.7 ANTIBODIES | [2012/36] | French: | MODIFICATION FONCTIONNELLE DES ANTICORPS ANTI-NAV 1.7 | [2012/36] | Entry into regional phase | 29.05.2012 | National basic fee paid | 29.05.2012 | Designation fee(s) paid | 29.05.2012 | Examination fee paid | Examination procedure | 29.05.2012 | Examination requested [2012/36] | 13.12.2012 | Amendment by applicant (claims and/or description) | 21.12.2016 | Despatch of a communication from the examining division (Time limit: M06) | 28.06.2017 | Reply to a communication from the examining division | 06.02.2018 | Despatch of a communication from the examining division (Time limit: M06) | 14.08.2018 | Reply to a communication from the examining division | 23.09.2019 | Cancellation of oral proceeding that was planned for 01.10.2019 | 01.10.2019 | Date of oral proceedings (cancelled) | 24.10.2019 | Communication of intention to grant the patent | 30.01.2020 | Fee for grant paid | 30.01.2020 | Fee for publishing/printing paid | 30.01.2020 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 21.12.2016 | Opposition(s) | 14.12.2020 | No opposition filed within time limit [2021/07] | Fees paid | Renewal fee | 31.10.2012 | Renewal fee patent year 03 | 31.10.2013 | Renewal fee patent year 04 | 31.10.2014 | Renewal fee patent year 05 | 02.11.2015 | Renewal fee patent year 06 | 31.10.2016 | Renewal fee patent year 07 | 02.11.2017 | Renewal fee patent year 08 | 31.10.2018 | Renewal fee patent year 09 | 31.10.2019 | Renewal fee patent year 10 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 27.10.2010 | AL | 11.03.2020 | AT | 11.03.2020 | CY | 11.03.2020 | CZ | 11.03.2020 | DK | 11.03.2020 | EE | 11.03.2020 | ES | 11.03.2020 | FI | 11.03.2020 | HR | 11.03.2020 | IT | 11.03.2020 | LT | 11.03.2020 | LV | 11.03.2020 | MC | 11.03.2020 | MK | 11.03.2020 | MT | 11.03.2020 | NL | 11.03.2020 | PL | 11.03.2020 | RO | 11.03.2020 | RS | 11.03.2020 | SE | 11.03.2020 | SI | 11.03.2020 | SK | 11.03.2020 | SM | 11.03.2020 | TR | 11.03.2020 | BG | 11.06.2020 | NO | 11.06.2020 | GR | 12.06.2020 | IS | 11.07.2020 | PT | 05.08.2020 | GB | 27.10.2020 | IE | 27.10.2020 | LU | 27.10.2020 | BE | 31.10.2020 | CH | 31.10.2020 | FR | 31.10.2020 | LI | 31.10.2020 | [2022/31] |
Former [2022/30] | HU | 27.10.2010 | |
AL | 11.03.2020 | ||
AT | 11.03.2020 | ||
CY | 11.03.2020 | ||
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
MC | 11.03.2020 | ||
MT | 11.03.2020 | ||
NL | 11.03.2020 | ||
PL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SI | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
TR | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
GB | 27.10.2020 | ||
IE | 27.10.2020 | ||
LU | 27.10.2020 | ||
BE | 31.10.2020 | ||
CH | 31.10.2020 | ||
FR | 31.10.2020 | ||
LI | 31.10.2020 | ||
Former [2022/27] | HU | 27.10.2010 | |
AT | 11.03.2020 | ||
CY | 11.03.2020 | ||
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
MC | 11.03.2020 | ||
MT | 11.03.2020 | ||
NL | 11.03.2020 | ||
PL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SI | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
TR | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
GB | 27.10.2020 | ||
IE | 27.10.2020 | ||
LU | 27.10.2020 | ||
BE | 31.10.2020 | ||
CH | 31.10.2020 | ||
FR | 31.10.2020 | ||
LI | 31.10.2020 | ||
Former [2022/26] | AT | 11.03.2020 | |
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
MC | 11.03.2020 | ||
NL | 11.03.2020 | ||
PL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SI | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
TR | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
GB | 27.10.2020 | ||
IE | 27.10.2020 | ||
LU | 27.10.2020 | ||
BE | 31.10.2020 | ||
CH | 31.10.2020 | ||
FR | 31.10.2020 | ||
LI | 31.10.2020 | ||
Former [2021/46] | AT | 11.03.2020 | |
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
MC | 11.03.2020 | ||
NL | 11.03.2020 | ||
PL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SI | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
GB | 27.10.2020 | ||
IE | 27.10.2020 | ||
LU | 27.10.2020 | ||
BE | 31.10.2020 | ||
CH | 31.10.2020 | ||
FR | 31.10.2020 | ||
LI | 31.10.2020 | ||
Former [2021/38] | AT | 11.03.2020 | |
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
MC | 11.03.2020 | ||
NL | 11.03.2020 | ||
PL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SI | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
GB | 27.10.2020 | ||
LU | 27.10.2020 | ||
BE | 31.10.2020 | ||
CH | 31.10.2020 | ||
FR | 31.10.2020 | ||
LI | 31.10.2020 | ||
Former [2021/37] | AT | 11.03.2020 | |
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
MC | 11.03.2020 | ||
NL | 11.03.2020 | ||
PL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SI | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
LU | 27.10.2020 | ||
BE | 31.10.2020 | ||
CH | 31.10.2020 | ||
FR | 31.10.2020 | ||
LI | 31.10.2020 | ||
Former [2021/36] | AT | 11.03.2020 | |
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
MC | 11.03.2020 | ||
NL | 11.03.2020 | ||
PL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SI | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
LU | 27.10.2020 | ||
BE | 31.10.2020 | ||
FR | 31.10.2020 | ||
Former [2021/35] | AT | 11.03.2020 | |
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
MC | 11.03.2020 | ||
NL | 11.03.2020 | ||
PL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SI | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
LU | 27.10.2020 | ||
FR | 31.10.2020 | ||
Former [2021/31] | AT | 11.03.2020 | |
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
MC | 11.03.2020 | ||
NL | 11.03.2020 | ||
PL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SI | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
LU | 27.10.2020 | ||
Former [2021/10] | AT | 11.03.2020 | |
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
NL | 11.03.2020 | ||
PL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SI | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
Former [2021/09] | AT | 11.03.2020 | |
CZ | 11.03.2020 | ||
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
IT | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
NL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
Former [2021/08] | CZ | 11.03.2020 | |
DK | 11.03.2020 | ||
EE | 11.03.2020 | ||
ES | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
NL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
Former [2020/50] | CZ | 11.03.2020 | |
EE | 11.03.2020 | ||
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
NL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
Former [2020/49] | CZ | 11.03.2020 | |
FI | 11.03.2020 | ||
HR | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
NL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SK | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
Former [2020/48] | FI | 11.03.2020 | |
HR | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
NL | 11.03.2020 | ||
RO | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
SM | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
PT | 05.08.2020 | ||
Former [2020/47] | FI | 11.03.2020 | |
HR | 11.03.2020 | ||
LT | 11.03.2020 | ||
LV | 11.03.2020 | ||
NL | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
Former [2020/46] | FI | 11.03.2020 | |
HR | 11.03.2020 | ||
LV | 11.03.2020 | ||
NL | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
IS | 11.07.2020 | ||
Former [2020/45] | FI | 11.03.2020 | |
HR | 11.03.2020 | ||
LV | 11.03.2020 | ||
NL | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
Former [2020/39] | FI | 11.03.2020 | |
HR | 11.03.2020 | ||
LV | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
BG | 11.06.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
Former [2020/38] | FI | 11.03.2020 | |
HR | 11.03.2020 | ||
LV | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
NO | 11.06.2020 | ||
GR | 12.06.2020 | ||
Former [2020/37] | FI | 11.03.2020 | |
HR | 11.03.2020 | ||
LV | 11.03.2020 | ||
RS | 11.03.2020 | ||
SE | 11.03.2020 | ||
NO | 11.06.2020 | ||
Former [2020/35] | FI | 11.03.2020 | |
NO | 11.06.2020 | Cited in | International search | [XA]WO2007109324 (XENON PHARMACEUTICALS INC [CA], et al) [X] 1 * abstract * [A] 2-30; | [A]WO2009033027 (MEDTRONIC INC [US], et al) [A] 1-30 * abstract *; | [XA] - MCGOWAN ERIN ET AL, "A Peripherally Acting Na(v)1.7 Sodium Channel Blocker Reverses Hyperalgesia and Allodynia on Rat Models of Inflammatory and Neuropathic Pain", ANESTHESIA & ANALGESIA, (200909), vol. 109, no. 3, ISSN 0003-2999, pages 951 - 958, XP002618055 [X] 1 * the whole document * [A] 2-30 DOI: http://dx.doi.org/10.1213/ane.0b013e3181b01b02 | [A] - MEIRI ET AL, "Detection of cell surface sodium channels by monoclonal antibodies - could the channels become exposed to the external surface and 'down regulated' by binding to antibodies?", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 368, no. 1, doi:DOI:10.1016/0006-8993(86)91061-9, ISSN 0006-8993, (19860312), pages 188 - 192, (19860312), XP024274584 [A] 1-30 * the whole document * DOI: http://dx.doi.org/10.1016/0006-8993(86)91061-9 | Examination | WO2007023298 | WO2006040357 | - CHIONI A M ET AL, "A novel polyclonal antibody specific for the Nav1.5 voltage-gated Na<+> channel 'neonatal' splice form", JOURNAL OF NEUROSCIENCE METHODS, ELSEVIER SCIENCE PUBLISHER B.V., AMSTERDAM, NL, vol. 147, no. 2, ISSN 0165-0270, (20050930), pages 88 - 98, (20050930), XP027670521 | - XU SHANG-ZHONG ET AL, "Generation of functional ion-channel tools by E3 targeting", NATURE BIOTECHNOLOGY, GALE GROUP INC, (20051001), vol. 23, no. 10, doi:10.1038/NBT1148, ISSN 1087-0156, pages 1289 - 1293, XP002415111 DOI: http://dx.doi.org/10.1038/nbt1148 | by applicant | WO9202551 | WO2004051268 | WO2004106377 | WO9109967 | WO2005003169 | WO2005003170 | WO2005003171 | WO2010035012 | WO9222853 | WO2005113605 | WO9749805 | WO03050531 | US2007041972 | WO2008090958 | US2004191265 | US5585089 | WO9002809 | WO9110737 | WO9201047 | WO9218619 | WO9311236 | WO9515982 | WO9520401 | US5698426 | US5223409 | US5403484 | US5580717 | US5427908 | US5750753 | US5821047 | US5571698 | US5516637 | US5780225 | US5658727 | US5733743 | US5969108 | EP0546073 | US5545806 | US5569825 | US5625126 | US5633425 | US5661016 | US5770429 | EP0438474 | EP0463151 | US4816397 | US6331415 | EP0996622 | US7456187 | US4741900 | WO2005117984 | US5219996 | US5667425 | WO9825971 | WO2008038024 | US5677425 | US7521541 | WO9820734 | - DOYLE ET AL., SCIENCE, (1998), vol. 280, page 69 | - JIANG ET AL., NATURE, (2003), vol. 423, page 33 | - LONG ET AL., SCIENCE, (2005), vol. 309, page 897 | - LLINAS ET AL., J. PHYSIOL., (1980), vol. 305, pages 197 - 213 | - KOSTYUK ET AL., NEUROSCIENCE, (1981), vol. 6, pages 2423 - 2430 | - BOSSU ET AL., NEUROSCI. LETT., (1981), vol. 51, pages 241 - 246 | - GILLY ET AL., NATURE, (1984), vol. 309, pages 448 - 450 | - FRENCH ET AL., NEUROSCI. LETT., (1985), vol. 56, pages 289 - 294 | - IKEDA ET AL., J. NEUROPHYSIOL., (1986), vol. 55, pages 527 - 539 | - JONES ET AL., J. PHYSIOL., (1987), vol. 389, pages 605 - 627 | - GILLY ET AL., J. NEUROSCI., (1989), vol. 9, pages 1362 - 1374 | - GONOI ET AL., J. NEUROSCI., (1985), vol. 5, pages 2559 - 2564 | - WEISS ET AL., SCIENCE, (1986), vol. 233, pages 361 - 364 | - PNAS, (20011106), vol. 98, no. 23, pages 13373 - 13378 | - THE JOURNAL OF NEUROSCIENCE 22, (2004), vol. 24, no. 38, pages 832 - 836 | - KLIONSKY ET AL., THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (2006), vol. 319, no. 1, pages 192 - 198 | - BABCOOK, J. ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, no. 15, pages 7843 - 7848 | - CHOTHIA, C.; LESK, A.M., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917 | - VAUGHAN ET AL., NATURE BIOTECHNOLOGY, (1998), vol. 16, pages 535 - 539 | - REICHMANN ET AL., NATURE, (1998), vol. 332, pages 323 - 324 | - HOLLIGER; HUDSON, NATURE BIOTECH., (2005), vol. 23, no. 9, pages 1126 - 1136 | - ADAIR; LAWSON, DRUG DESIGN REVIEWS - ONLINE, (2005), vol. 2, no. 3, pages 209 - 217 | - VERMA ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, (1998), vol. 216, pages 165 - 181 | - HAMERS ET AL., NATURE, (1993), vol. 363, pages 446 - 448 | - MUYLDERMANS ET AL., TRENDS. BIOCHEM.SCI., (2001), vol. 26, pages 230 - 235 | - DECANNIERE ET AL., J. MOL.BIOL, (2000), vol. 300, pages 83 - 91 | - NGUYEN ET AL., ADV. IMMUNOL., (2001), vol. 79, pages 261 - 296 | - LAUWEREYS ET AL., EMBO J, (1998), vol. 17, pages 3512 - 3520 | - DESMYTER ET AL., NAT.STRUCT.BIOL., (1996), vol. 3, pages 803 - 811 | - DE GENST ET AL., PNAS, (2006), vol. 103, no. 12, pages 4586 - 4591 | - STANFIELD ET AL., SCIENCE, (2004), vol. 305, pages 1770 - 1773 | - LAUWEREYS ET AL., EMBO J., (1998), vol. 17, no. 13, pages 3512 - 20 | - LIU ET AL., BMC BIOTECHNOL., (2007), vol. 7, page 78 | - SAERENS ET AL., J. BIOL. CHEM., (2004), vol. 279, no. 5, pages 51965 - 72 | - TAO ET AL., J. EXP.MED, (1991), vol. 173, pages 1025 - 1028 | - TAO ET AL., J. EXP.MED, (1993), vol. 178, pages 661 - 667 | - ZUCKER ET AL., CANC RES, (1998), vol. 58, pages 3905 - 3908 | - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, pages 495 - 497 | - KOZBOR ET AL., IMMUNOLOGY TODAY, (1983), vol. 4, page 72 | - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, INC., (1985), pages 77 - 96 | - BRINKMAN ET AL., J IMMUNOL. METHODS, (1995), vol. 182, pages 41 - 50 | - AMES ET AL., J LMMUNOL. METHODS, (1995), vol. 184, pages 177 - 186 | - KETTLEBOROUGH ET AL., EUR. J IMMUNOL., (1994), vol. 24, pages 952 - 958 | - PERSIC ET AL., GENE, (1997), vol. 187, pages 9 - 18 | - BURTON ET AL., ADVANCES IN IMMUNOLOGY, (1994), vol. 57, pages 191 - 280 | - WARD ET AL., NATURE, (1989), vol. 341, page 544 | - ORLANDI ET AL., PROC.NATL.ACAD.SCI. USA, (1989), vol. 86, page 3833 | - RIECHMANN ET AL., NATURE, (1988), vol. 322, page 323 | - BIRD ET AL., SCIENCE, (1988), vol. 242, page 423 | - MOUNTAIN; ADAIR, BIOTECHNOL. GENET. ENG. REV, (1992), vol. 10, pages 1 - 142 | - ANGAL ET AL., MOLECULAR IMMUNOLOGY, (1993), vol. 30, no. 1, pages 105 - 108 | - HARRIS, RJ., JOURNAL OF CHROMATOGRAPHY, (1995), vol. 705, pages 129 - 134 | - NYGREN; UHLEN, CURRENT OPINION IN STRUCTURAL BIOLOGY, (1997), vol. 7, pages 463 - 469 | - MOL PHARMACOL, (2008), vol. 74, pages 1476 - 1484 | - RA HILL; S RUDRA; B PENG; DS ROANE; JK BOUNDS; Y G, A ADLOO; T LU, BIOORG MED CHEM, (2003), vol. 11, pages 2099 - 113 | - MCGOWAN ET AL., ANESTHESIA AND ANALGESIA, (200909), vol. 109, no. 3 | - ANGER ET AL., J. MED. CHEM., (2001), vol. 44, no. 2, page 115 | - HOYT ET AL., BIOORG. MED. CHEM. LETT., (2007), vol. 17, page 6172 | - YANG ET AL., J. MED. CHEM., (2004), vol. 47, page 1547 | - BENES ET AL., J. MED. CHEM., (1999), vol. 42, page 2582 | - BIOORGANIC AND MEDICAL CHEMISTRY LETTERS, (20090601), vol. 19, no. 11, pages 3063 - 3066 | - CHAPMAN, ADVANCED DRUG DELIVERY REVIEWS, (2002), vol. 54, pages 531 - 545 | - LEONG ET AL., CYTOKINE, (2001), vol. 16, pages 106 - 119 | - CHAPMAN ET AL., NATURE BIOTECHNOLOGY, (1999), vol. 17, pages 780 - 783 | - BARLOS, K.; GATOS, D.; KUTSOGIANNI, S.; PAPAPHOTIOU, G.; POULOS, C.; TSEGENIDIS, T., INT. J. PEPT. PROTEIN RES., (1991), vol. 38, no. 6, pages 562 - 568 | - KESSLER H ET AL., COMPUTER AIDED DRUG DESIGN, (1989), pages 461 - 484 | - DEKKER M ET AL., J. PEPTIDE RESEARCH, (1990), vol. 35, pages 287 - 300 | - GURRATH M. ET AL., EUR. J. BIOCHEM., (1992), vol. 210, pages 911 - 921 | - IZUMIYA N. ET AL., BIOPOLYMERS, (1981), vol. 20, pages 1785 - 1791 | - BRADY S. F. ET AL., Peptides, Structure and Function, PIERCE CHEMICAL COMPANY, (1983), pages 127 - 130 | - HE J. X. ET AL., LETT. PEPTIDE SCI., (1994), vol. 1, pages 25 - 30 | - KESSLER H ET AL., Computer-aided drug design, methods and applications, MARCEL DEKKER, (1989), pages 461 - 484 | - TONIOLO C., INT. J. PEPT. PROTEIN RES., (1990), vol. 35, pages 287 - 300 | - TICKLE ET AL., JALA, (2009), vol. 14, no. 5, pages 303 - 307 |